1.21  0.06 (5.22%)		04-13 16:00
Open: 1.175 High: 1.2977 Volume: 488,667		Pre. Close: 1.15 Low: 1.17 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	2.04	1-year :	2.47
Resists	First :	1.74	Second :	2.11
Pivot price	1.59
Supports	First :	1.14	Second :	0.95
MAs	MA(5) :	1.26	MA(20) :	1.69
	MA(100) :	2.27	MA(250) :	8.04
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	4.3	D(3) :	4.7
RSI	RSI(14): 25.2
52-week	High :	55	Low :	1.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed above bottom band by 14.5%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.3 - 1.31	1.31 - 1.32
Low:	1.15 - 1.16	1.16 - 1.17
Close:	1.19 - 1.21	1.21 - 1.23

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Tue, 10 Mar 2026
Genprex brings gene therapies to 3,700-strong Lisbon biotech event - Stock Titan

Mon, 23 Feb 2026
Genprex receives Japanese and European patents for cancer therapy - Investing.com

Mon, 23 Feb 2026
Genprex stock jumps on Japan, Europe patent approvals - Investing.com

Mon, 23 Feb 2026
Japan, EU patents shield gene therapy combo for small cell lung cancer - Stock Titan

Thu, 15 Jan 2026
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative

Fri, 09 Jan 2026
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	-10 (M)
Shares Float	0 (M)
Held by Insiders	1.63e+006 (%)
Held by Institutions	2.25e+006 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-1.633e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	261.61
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-273.4 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	479990
Forward Dividend	455580
Dividend Yield	39668600%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.